House Subcommittee Schedules Hearing on PDUFA, GDUFA and BsUFA Reauthorizations

February 1, 2022

The House Energy and Commerce Health Subcommittee will hold a hearing Thursday on reauthorizing FDA user fee programs for prescription drugs, generics and biosimilars, ahead of the programs’ expiration slated for Sept. 30.

The lawmakers will hear testimony from high-ranking FDA officials and stakeholders in the hearing, which is scheduled to start at 10:30 a.m. ET.

In mid-January, the FDA submitted its user fee commitments negotiated with industry to lawmakers, allowing Congress to start work on legislation to reauthorize the programs for fiscal years 2023 through 2027.

View today's stories